Challenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
|
|
- Audrey Harrell
- 5 years ago
- Views:
Transcription
1 Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
2
3
4 OS PCG 15.8 vs GC 12.7 NS
5
6
7
8 Cisplatin ineligible
9 Second-line chemotherapy for muscle invasive bladder cancer: There are no definitive recommendations for second-line therapy Chemotherapy options may include drugs such as cisplatin, gemcitabine, pemetrexed, carboplatin, vinblastine, and bleomycin.
10
11 OS 6.9 vs 4.6 months vinflunine
12 Unmet need: Chemotherapy For Advanced Stage stills has limit efficacy Median OS for untreated stage IV: 3-4 months Bladder cancer is a chemo-sensitive tumor ; However, Chemotherapy intervention results in prolongation of median OS to mo 3-year survival: 15-20%
13
14
15
16 Large Immunotherapy Published Bladder Cancer Clinical Trials Presented By Andrea Apolo at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
17 Slide 4 Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
18 1 st line
19 2 nd line
20 New Treatment Options for Patients With <br />Advanced Metastatic Urothelial Carcinoma Presented By Andrea Apolo at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
21
22
23
24
25 1 st line in cisplatin ineligible Atezolizumab as 1L Therapy in Cisplatin-Ineligible Locally Advanced/Metastatic Urothelial Carcinoma: IMvigor210 Cohort 1 Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium
26 IMvigor210 Cohort 2: Study Design<br />Basis for Accelerated Approval Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium
27
28 Frontline Therapy for UC: Cis-Ineligible Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium
29 1 st line
30 KEYNOTE-045 Study Design (NCT ) Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
31 Assessments Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
32 Overall Survival: Total Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
33 Updated Efficacy From IMvigor210: <br />Atezolizumab in Platinum-Treated Locally Advanced/Metastatic Urothelial Carcinoma (muc) Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium
34 IMvigor210 Cohort 2: Study Design<br />Basis for Accelerated Approval Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium
35
36 IMvigor 210 Safety<br />Summary Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium
37 Keynote 045 Treatment-Related AEs Occurring in 10% of Patientsa Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
38 AEs of Interest Occurring in 1 Patienta,b Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
39
40 Phase 3 IMvigor211 Study Design Presented By Andrea Apolo at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
41 Atezolizumab PD-L1 Assay:<br /> Presented By Andrea Apolo at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
42 IMvigor211: OS Analysis: IC2/3 Population Presented By Andrea Apolo at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
43
44 Comparison of key parameters in the randomised phase III studies. Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
45 10.3
46
47
48 OS by TMB Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
49 OS by TMB and PD-L1 Status Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
50 2 nd line
51 Take home massage Consensus statement for platinum refractory disease. Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
52 Consensus statement: front line therapy. Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
53 Summary: single agent immune therapy in platinum refractory disease. Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
54 Summary: single agent immune therapy in chemotherapy naïve patients. Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
Updates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationAVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationDisclosure. Astellas. Research funding. Advisory board (to institute) Roche/Genentech Astra Zeneca/Medimmune Astellas
Disclosure Activity Company Research funding Advisory board (to institute) Astellas Roche/Genentech Astra Zeneca/Medimmune Astellas Immunotherapy for urothelial cell carcinoma A NEW HOPE Michiel van der
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationUrothelial Carcinoma Highlights
Urothelial Carcinoma Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano European Association of Urology Research Foundation Disclosures Consulting or Advisory Role: Company:
More informationChallenging Genitourinary Tumors: What s New in 2017
Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an
More informationNeoplasie uroteliali 2017 Highlights. Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Neoplasie uroteliali 2017 Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Disclosures Consulting or Advisory Role: Company: Roche, Bayer, Merck & Co. Inc., Astra
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationIMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER
IMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Hematology/Oncology Fox Chase Cancer Center, Temple Health Neoadjuvant
More informationIntegrating Immunotherapy into Urologic Oncology: The New Urothelial Cancer Paradigm
Immunotherapy in Urothelial Cancer: Where are We Now & Where are We Going? Arjun Balar, MD Director of Genitourinary Medical Oncology Program NYU Langone Medical Center New York, NY Bladder Cancer Therapeutic
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationOptimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL
Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma Moran Gadot M.D SHEBA Medical Center ISRAEL Disclosures none All (eligible) patients should get chemotherapy
More informationNeoplasie uroteliali Posters & oral presentations
UPDATES and NEWS from the Genitourinary Cancers Symposium 3 Marzo 2017, Milano Neoplasie uroteliali Posters & oral presentations Cristina Masini Oncologia Medica IRCCS-Arcispedale S.Maria Nuova - Reggio
More informationCancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable
Cancer Drugs Fund Managed Access Agreement Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationRoche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary
More informationEmerging Role of Immunotherapy in Advanced Urothelial Carcinoma
Current Oncology Reports (2018) 20:48 https://doi.org/10.1007/s11912-018-0693-y GENITOURINARY CANCERS (DP PETRYLAK AND JW KIM, SECTION EDITORS) Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationRoche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Media Release Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides
More informationAdvanced Bladder Cancer: Check Mate or Check Point Inhibitors
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors Daniel P Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow
More informationApproved checkpoint inhibitors in bladder cancer: which drug should be used when?
788310TAM0010.1177/1758835918788310Therapeutic Advances in Medical OncologyP Ghatalia, M Zibelman research-article20182018 Therapeutic Advances in Medical Oncology Review Approved checkpoint inhibitors
More informationTHE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationBristol-Myers Squibb. Request for Educational Activity (RFE)
Bristol-Myers Squibb Independent Medical Education Request for Educational Activity (RFE) Date RFP Code Therapeutic Area Areas of Interest Educational Design Intended Audience Budget Accreditation Geographic
More informationINMUNOTERAPIA II. Dra. Virginia Calvo
INMUNOTERAPIA II Dra. Virginia Calvo LBA53. IMpower130. Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with o without atezolizumab
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationTechnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta492
Atezolizumab for untreated PD- L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta492
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationSociety for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Kamat et al. Journal for ImmunoTherapy of Cancer (2017) 5:68 DOI 10.1186/s40425-017-0271-0 POSITION ARTICLE AND GUIDELINES Society for Immunotherapy of Cancer consensus statement on immunotherapy for the
More informationRoche Investor Relations ASCO Planner 2018
Roche Investor Relations ASCO Planner 2018 Friday, June 1 Session Title: Hematologic Malignancies Plasma Cell Dyscrasia Date: Fri, June 1 Time: 2:45 PM - 5:45 PM Speaker Name: Luciano J. Costa 3:57 PM
More informationExploring New Strategies in Bladder Cancer
Exploring New Strategies in Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, Genitourinary Translational Working Group Co-Director, Signal Transduction Program Smilow Cancer
More informationLa realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga
La realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre. I +
More informationI Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
I Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena XII Corso di aggiornamento AIRTUM per operatori dei Registri Tumori Reggio Emilia
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationUrinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
More informationImmunotherapy and urothelial carcinoma. Yohann Loriot
Immunotherapy and urothelial carcinoma Yohann Loriot Immunothérapie en clinique : Cancers de vessie Où en sommes nous? Données phase I/II FDA «breakthrough designation» Prochaines étapes? Immunothérapie
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationBiomarkers for immunotherapy in bladder cancer: a moving target
Aggen and Drake Journal for ImmunoTherapy of Cancer (2017) 5:94 DOI 10.1186/s40425-017-0299-1 REVIEW Biomarkers for immunotherapy in bladder cancer: a moving target David H. Aggen * and Charles G. Drake
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May
BRAND NAME Keytruda GENERIC NAME Pembrolizumab MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL Non-small cell lung cancer (NSCLC) indication: May 10, 2017 Urothelial carcinoma indication: May 18, 2017
More informationImmunotherapy in GU Cancers. Dr Ravindran Kanesvaran Medical Oncologist National Cancer Centre Singapore
Immunotherapy in GU Cancers Dr Ravindran Kanesvaran Medical Oncologist National Cancer Centre Singapore 1 Disclosures Speaker Bureau: Pfizer, J&J, Sanofi, Novartis, MSD Advisory Board/ Consultant: GSK,
More informationpatients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease
patients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease First, perc agreed with CGP that the diagnosis of urothelial
More informationSCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:
ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationMetastatic Bladder Cancer: Immunotherapy. Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-IMIM
Metastatic Bladder Cancer: mmunotherapy Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-MM September 19 th, 2018 Disclosures Advisory role: Genentech, Merck, Pfizer,
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationNOVÉ MOŽNOSTI LÉČBY NÁDORŮ MOČOVÉHO MĚCHÝŘE A JEJICH ZAŘAZENÍ DO ALGORITMU LÉČBY. Jindřich Fínek LF UK a FN Plzeň
NOVÉ MOŽNOSTI LÉČBY NÁDORŮ MOČOVÉHO MĚCHÝŘE A JEJICH ZAŘAZENÍ DO ALGORITMU LÉČBY Jindřich Fínek LF UK a FN Plzeň 1 KARCINOM MOČOVÉHO MĚCHÝŘE INCIDENCE A MORTALITA 2 KARCINOM MOČOVÉHO MĚCHÝŘE ZASTOUPENÍ
More informationImmunoterapia nella malata avanzata. Daniele Raggi Fondazione IRCCS Isttuto Nazionale dei Tumori, Milano
Immunoterapia nella malata avanzata Daniele Raggi Fondazione IRCCS Isttuto Nazionale dei Tumori, Milano Five checkpoint inhibitors now approved for UC! BCG Atezolizumab (US/EU) (2L) Atezolizumab (US/EU)
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationRoche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationRECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer
RECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer IX CIS and EURASIA ONCOLOGY and RADOLOGY CONGRESS, ONCOUROLOGY SESSION 16 June 2016 Richard E Greenberg, MD, FACS Chief Urologic Oncology, Fox Chase
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationCarcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia
Carcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia New target, new agent (James Brugarolas) Atezolizumab + Bevacizumab and PD-L1
More informationCheckpoint inhibitors in the treatment of urological malignancies
Review Checkpoint inhibitors in the treatment of urological malignancies Lazar S Popovic, 1,2 Gorana Matovina-Brko, 1,2 Maja Popovic 1,2 To cite: Popovic LS, Matovina-Brko G, Popovic M. Checkpoint inhibitors
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationInvestor Update. Basel, 14 April 2018
Investor Update Basel, 14 April 2018 Roche to present data on (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationFirst phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase
More informationMedia Release. Basel, 6 th February 2018
Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationReview Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
Review Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions Shilpa Gupta 1,, David Gill 2,, Austin Poole 2 and Neeraj Agarwal 2, * 1 Masonic Cancer Center, University of Minnesota,
More informationPhase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
Bladder Cancer 2 (2016) 111 117 DOI 10.3233/BLC-150038 IOS Press Research Report 111 Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationTreatment of muscle invasive bladder cancer. ie: pt2. N. Mottet
Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients
More informationBEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084. GCIG Meeting
BEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084 GCIG Meeting Ana Oaknin, MD PhD Head of Gynecologic Cancer Program. Vall d Hebron Institute of Oncology(VHIO). Vall d Hebron University Hospital. GEICO
More informationPD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer
Journal of Cancer Treatment and Research 2017; 5(5): 71-80 http://www.sciencepublishinggroup.com/j/jctr doi: 10.11648/j.jctr.20170505.11 ISSN: 2376-7782 (Print); ISSN: 2376-7790 (Online) PD1/PDL-1 Inhibitors:
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More information